ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Nanogel-based delivery of dequalinium chloride: A novel approach for antimicrobial and controlled drug release.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunomodulator loaded microneedle arrays for targeted intradermal drug delivery to skin tumors.Drug delivery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dequalinium chloride (DQC) is a potent antimicrobial agent; however, its therapeutic application is limited due to poor solubility, rapid degradation, and short half-life. In this study, we developed a nanogel-based delivery system to provide stability, bioavailability, and controlled release of DQC, subsequently improving antimicrobial impact. Carbopol 940 and PEG 6000 were used for the synthesis of the nanogel, which was characterized for physicochemical properties, drug entrapment, and release kinetics. Differential Scanning Calorimetry (DSC), and X-ray Diffraction (XRD) confirmed the successful encapsulation and amorphous nature, whereas Thermogravimetric Analysis (TGA) validated improved thermal stability. The nanogel showed a high entrapment efficiency of 90%, and the drug was released sustained according to a non-Fickian diffusion mechanism with 86.23% cumulative release in 24 h. As per antimicrobial activity, it was observed that the developed formulation showed better inhibition against Escherichia coli and Staphylococcus aureus than free drug solutions. Thus, the findings indicate that the developed nanogel formulation can be considered a worthy advanced antimicrobial delivery system with controlled drug release.
Indexed as
Identifiers
40338320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.